Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema

Inclusion Criteria: * Written informed consent to participate in the study and ability to fulfil all study requirements * Male or female patients aged \>=18 years * Patients with ACE induced angioedema (grade II-III) with imminent airway obstruction admitted to an Emergency department * Patient is being treated with ACEi * Patient must have acute angioedema attack caused by ACEi * Treatment should be administered within 10 hours after onset of the angioedema * Patients with angioedema of the head and/or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx) * Male participants and female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country * Signed patient information consent form Exclusion Criteria: * Diagnosis of angioedema of other genesis: e.g. hereditary angioedema, C1-inhibitor deficiency, allergic edema, anaphylaxis, insect bite, trauma, abscess, local inflammation, local tumour, post-operative or post-radiogenic edema, salivary gland disorders * Participation in a clinical study in the past 30 days * Patients with simultaneous itchiness of skin (acute urticaria) * Patients with a history of angioedema before taking ACEi * History of hypersensitivity to any of the study drugs or medicine with a similar chemical structure. * Pregnancy and/or breastfeeding * Mental retardation of the patient with restriction of general judgment and awareness * History of drug abuse (including alcohol and alcoholic liver disorders) * Potentially unreliable patients * Patients who are not suitable for the study in the opinion of the investigator